Asceneuron Sa Is A Clinical Stage Biotech Company Based In Lausanneswitzerlandwith Additional Operations In San Franciscocathe Company Focuses On Discovering And Developing Therapeutics For Neurodegenerative Disordersparticularly Targeting Conditions Like Alzheimerae S Diseaseparkinsonae S Diseaseand Orphan Tauopathies Asceneuron Specializes In Creating Orally Bioavailable Therapeutics That Target Tau Protein Aggregationa Key Factor In Neurodegenerative Diseasestheir Product Pipeline Includes Asn90An O Glcnacaseogainhibitor Licensed To Ferrer Pharmaceuticals For Treating Progressive Supranuclear Palsyand Asn51A Promising Oga Inhibitor Under Development For Alzheimerae S Diseasethe Company Is Actively Engaged In Clinical Trials And Preclinical Development To Advance Treatments For Various Neurodegenerative Conditions Driven By A Mission To Enhance The Lives Of Patients With Neurodegenerative Diseasesasceneuron Is Committed To Innovative Treatment Solutionsthe Company Values Collaboration Among Its Dedicated Team Of Scientists And Drug Developers To Address Significant Unmet Medical Needs In This Field
